On the stock market since 2000, it operates in the world of health and science. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Revenue is spread across several lines; no single product carries the company.
Average growth of 18% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Over the last 3 years, sales grew about 18% a year on average.
The company sells $538.6M a year; the problem isn’t sales — it’s costs running above that number.
A loss of $48.5M against $538.6M in annual sales.
The price action doesn’t yet back an upward turn. Council score: 0/10.
On our five-subject report card, CPHD sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: CPHD has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.